Remarkable success has been achieved by targeting oncogenic gene fusions including diverse tyrosine kinase inhibitors against fusions involving ALK, ROS1, RET, FGFR1/2/3, and NTRK1/2/3 in non-small-cell lung cancer and across a wide spectrum of cancer types [4–7]. The gene discussed is RET; the disease is cancer.